{"filing":{"accession_number":"0002007919-26-000033","cik":"0002007919","ticker":"INBX","company_name":"Inhibrx Biosciences, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"inhibrx-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm"},"events":[{"id":11021,"run_id":9660,"accession_number":"0002007919-26-000033","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The FDA accepted Inhibrx's Biologics License Application (BLA) for ozekibart (INBRX-109) with a PDUFA goal date of April 14, 2027, representing a material regulatory milestone in the company's clinical development program.","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7497,"accession_number":"0002007919-26-000033","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The FDA's acceptance of a BLA filing for ozekibart (INBRX-109) with a PDUFA goal date is a material regulatory milestone for a biopharmaceutical company, signaling progress toward potential product approval. However, this does not fit neatly into the standard 8-K event taxonomy—it is neither an earnings release, executive change, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, nor material litigation. This is a significant regulatory development that would affect investor assessment of the company's pipeline and prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:25.537923+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7498,"accession_number":"0002007919-26-000033","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced FDA acceptance of a BLA (Biologics License Application) for ozekibart with a PDUFA goal date of April 14, 2027. This is a material regulatory milestone for a biopharmaceutical company, as BLA acceptance and FDA review progression directly affect the probability and timing of product commercialization. However, this does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M\u0026A activity, or executive change), so \"other_material\" is the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:25.537923+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7497,"accession_number":"0002007919-26-000033","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The FDA's acceptance of a BLA filing for ozekibart (INBRX-109) with a PDUFA goal date is a material regulatory milestone for a biopharmaceutical company, signaling progress toward potential product approval. However, this does not fit neatly into the standard 8-K event taxonomy—it is neither an earnings release, executive change, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, nor material litigation. This is a significant regulatory development that would affect investor assessment of the company's pipeline and prospects, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:25.537923+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-06-15"},{"id":7498,"accession_number":"0002007919-26-000033","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced FDA acceptance of a BLA (Biologics License Application) for ozekibart with a PDUFA goal date of April 14, 2027. This is a material regulatory milestone for a biopharmaceutical company, as BLA acceptance and FDA review progression directly affect the probability and timing of product commercialization. However, this does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M\u0026A activity, or executive change), so \"other_material\" is the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:09:25.537923+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-06-15"}]}